NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
651 Norrbotten

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 208 3.5% 100 1.7% 14 0.2% 1 0.0% 1 0.0% 3 0.1% 5542 94.4% 5869 100.0%
ASCUS 103 23.3% 81 18.3% 44 10.0% . . . . . . 214 48.4% 442 100.0%
LSIL 70 17.2% 110 27.0% 80 19.7% 2 0.5% . . . . 145 35.6% 407 100.0%
Atypical glandular cells/AGC 2 16.7% 2 16.7% 2 16.7% 2 16.7% 2 16.7% . . 2 16.7% 12 100.0%
Unclear atypia . . . . 4 100.0% . . . . . . . . 4 100.0%
ASC-H 6 12.5% 8 16.7% 32 66.7% . . . . . . 2 4.2% 48 100.0%
HSIL 8 5.3% 7 4.7% 122 81.3% . . 6 4.0% . . 7 4.7% 150 100.0%
Suspected Adenocarcinom . . . . 1 33.3% 2 66.7% . . . . . . 3 100.0%
Squamous cell cancer . . . . 5 62.5% . . 3 37.5% . . . . 8 100.0%
Totalt 397 5.7% 308 4.4% 304 4.4% 7 0.1% 12 0.2% 3 0.0% 5912 85.2% 6943 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M80703, M81403, M83803, M83806